HOME >> BIOLOGY >> NEWS
Two-pronged attack targeting EGF receptor hinders cancer cell growth

Hitting the epidermal growth factor receptor (EGFR) both high and low with a combination of drugs for targeted cancer therapy curbs cancer cell growth more effectively than using the drugs each by themselves, researchers from the University of Wisconsin-Madison reported in the August 1 issue of the journal Cancer Research.

EGFR drives unregulated growth in many types of cancer, and the new molecular cancer drugs, cetuximab (Erbitux, ImClone), and gefitinib (Iressa, AstraZeneca) have recently gained FDA approval as therapeutics targeted at the EGFR to inhibit cancer cell proliferation. A third EGFR inhibiting drug, and erlotinib (Tarceva, Genentech), may have FDA approval within a year.

The Wisconsin study examined the combined effect of Erbitux with either Iressa or Tarceva to control growth of head and neck, prostate, and lung cancer cell lines grown in culture, and lung cancer tumors developing in animals.

Tandem application of either Erbitux and Iressa, or Erbitux and Tarceva, proved synergistically more effective than single drug treaent at several levels.

"The combination of Erbitux with either Iressa or Tarceva inhibited cancer cell growth both in cell culture and in live animals more effectively than any of the drugs alone," said the study's senior author, Paul Harari, M.D., associate professor of human oncology, University of Wisconsin Medical School and Comprehensive Cancer Center.

"The impact of these drugs in combination exceeded the effect each had on controlling the growth, cellular signaling, and tumor development when administered alone," added Shyhmin Huang, Ph.D., a senior scientist in Harari's laboratory and lead author on the publication.

The anti-EGFR drugs are of two types:

  • The monoclonal antibody Erbitux hits the EGFR high, binding to a specific site on the receptor outside the cell membrane. Erbitux blocks the receptor from responding to extracellular signals that tu
    '"/>


Contact: Russell Vanderboom, PhD
vanderboom@aacr.org
215-440-9300
American Association for Cancer Research
1-Aug-2004


Page: 1 2 3

Related biology news :

1. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
2. Smart gene therapy protects against damage from heart attack
3. Reading hexametric rhyme supports cardiac synchronization, especially after a heart attack
4. New standard to help diagnose heart attacks
5. Variation of gene associated with decreased risk of heart attack and stroke
6. Dampened hopes for transplanting bone marrow stem cells in heart attacks
7. Protein may help prevent autoimmune attacks
8. Biosensor-regulated gene therapy reduces heart attack damage in mice
9. Lion attacks on livestock in Africa are significant but manageable
10. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
11. Stem-cell therapy could have benefits and risks for heart-attack PTs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... , May 26, 2016 Despite ... see value in this space. Today,s pre-market research on ActiveWallSt.com ... Radius Health Inc. (NASDAQ: RDUS ), Cerus Corp. ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... company, today announced several positive developments that position the Company for the future. ... of the transaction, Craig F. Kinghorn has been appointed Chairman of the Board, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising ... been rated one of its top attractions. Fortune 500 companies, such as Illumina, ... a unique and intimate team-building experience. , Each event kicks off with an olive ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... fracture-specific plating options designed to address fractures of the distal tibia and fibula. ... The Acumed Ankle Plating System 3 is composed of seven plate families that ...
Breaking Biology Technology:
Cached News: